Michigan State University has identified microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer’s disease.
Chiesi Farmaceutici SpA has synthesized pyridazinyl amino derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported for be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Lead Discovery Center GmbH and Qli5 Therapeutics GmbH have described macrocyclic compounds acting as proteasome subunit β type-5 (PSMB5) inhibitors reported to be useful for the treatment of cancer, infections, inflammatory disorders, myasthenia gravis and transplant rejection.
Shijiazhuang Discovery Medicine Technology Co. Ltd. has divulged pranoprofen derivatives reported to be useful for the treatment of pain and eye disorders.
Kymera Therapeutics Inc. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently linked to an MDM2 targeting moiety through a linker and reported to be useful for the treatment of cancer.
RSS